Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Officials ACTC buying stock would not really be a good sign. If they did, someone would say, "insider info" and cause another kind of negative fuss.
Could somebody with a technical knowledge about Advanced Cell Technology's blood and platelet programs translate for me the amount of blood and/or platelets they can produce in terms of units? (average human has 12 units of blood). It would be nice to know how long it takes and how much they can produce from hesc vs ips as well.
Should be .15 may be a little pessimistic, ok, Like Maxim said, .45 is the should be price, but that is a target they feel we'll be at by the 4th quarter of this year. That is their conservative estimate.
The PPs should be around .15, don't get so excited.
Advanced Cell Technology can only make reference (PR) to the publication date the Friday before the Wednesday/Thursday it is published.
Ok, see that slide #4 has Lupus as in TBD status to start Phase I. The animal studies must be pretty darn impressive.
http://www.advancedcell.com/documents/0000/0481/act-corporate-presentation---bioceo---february-2014--print-version.pdf
Perhaps GSK is aware of what ACTC has in way of a treatment for Lupus.
"GSK has called it quits on its GSK2586184 treatment for lupus - which it's developing with Belgian biotech Galapagos (GLPGF) - after a Phase 2 study failed to demonstrate a positive effect."
From Seeking Alpha.
The relationship between FDA and ACTC will blaze a trail for cellular biotech, IMO. I agree, we are on the edge of something pretty good for investors and Advanced Cell Technology!
Here is a link to the FDA page regarding tissue issues.
insert-text-here
My understanding is that ACTC's product does not fall under this definition as the esc's are not listed in the
"derived from" list.
IMO, some of this may change based on this ACTC trial.
This may be obvious, but maybe it isn't. When we talk about stem cells, what ACTC is actually producing are fully differentiated stem cells, and the clinics that use them in the trials have referred to the operation as a tissue transplant. I don't know if Advanced Cell Technology will ever just inject stem cells. Even the eMSC are not really stem cells.
The words from Rome didn't come from ACTC company. The reference to the publication came from and investigative partner. Lets not blame what one brother says on another brother.
ACTC can make reference to a publication in NEJM the Friday before the next week publication. It's optional I suppose, but if they do PR this directly, then we can truly have that expectation. If it's in the publishers hands, ACTC doesn't decide when to publish, the publisher does.
When considering visual acuity gains, we should recall that they have everything to do with available viable photoreceptors.
I agree. It is well known that Induced stem cells have to be watched for a much longer period of time, just to make sure they don't revert to skin cells or whatever they once were. ACTC's embryonic stem cells are still the gold standard.
When stem cells are induced, think of them as imitation stem cells. They simply aren't as durable, or strong. When you repair your car, for example, depending on how long you want the repair to last, you can get a part from the salvage yard, or get a brand new part. Sure its easy to get junk yard parts, but why not get quality, brand new parts!
Capt Smith 77, ACTC's hesc method does not destroy the embryo, is it controversial because it does not harm the embryo?
What controversy? you may have misinformed yourself.
I must have missed something, "lawsuit against GR" I know there is an investigation, but I had not heard that any charges had been filed.
Heard a story on public radio this morning regarding stem cells. They stated flatly that embryonic stem cells require the destruction of the embryo. I recommend sending a email to your public radio station news to help inform them of the exception!
Minnesota's : newsroom@mpr.org
Regarding NEJM publication:
The Journal is published weekly, with a Thursday publication date. Each week’s content is made available online at 5PM Eastern time in the United States on Wednesday.
If an article has immediate clinical importance, the Journal may designate it for early release and publish it online before its appearance in print.
MM exploring the stop loss?
to the mid 9's after a coffee break. pps cheap now compared to a couple days from now!
up 13% for today....will it sit here in the mid 8 cent area for today?
up over 16% now!
up over 14% currently!
Over 6 million shares traded so far...up 8-9 %
The smart money already has a position! Get ready to watch the great pps races begin!
Lets not put emphasis where it is misplaced. If you look deeper into the reality of ACTC, they have already a line on 60 million dollars of financing. The SEC case is mostly a repayment of funds 3.5 million and an interest amount which totals to 4.1 million. They have a payment plan with the SEC, so don't try to say it is all due at once. TLD coming out soon, the financial scenery should improve tremendously.
This video has a GE rep. talking about the ACTC's success, could be a powerful connection
http://vimeo.com/78571115 Dr.
Tengion, Inc. : Tengion Announces Continued Clinical Progress in Its Two Lead Programs
01/13/2014 | 09:01am US/EasternRecommend:
0
-- Expansion Planned for Neo-Kidney Augment™ Swedish Phase 1 Clinical Trial to Include Ten Additional Patients; U.S. Phase 1 Clinical Trial Initiated --
-- Neo-Urinary Conduit™ U.S. Phase 1 Clinical Trial to Complete Patient Enrollment --
WINSTON-SALEM, N.C., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced continued clinical progress in its two lead programs, the Neo-Kidney Augment and the Neo-Urinary Conduit.
The Neo-Kidney Augment, which is intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease (CKD), was implanted in five CKD patients in 2013 in the ongoing Phase 1 clinical trial in Sweden. The Neo-Kidney Augment is safe and well tolerated in the five patients implanted to date. The Company now plans to expand enrollment in this trial to 15 patients. The Company also announced the initiation of a Phase 1 clinical trial in the U.S. under an open Investigational New Drug (IND) application for the Neo-Kidney Augment. Tengion will also complete patient enrollment in the ongoing U.S. Phase 1 clinical trial for its second lead program, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal.
"Our lead clinical programs have continued to make progress, placing Tengion at the forefront of regenerative medicine," commented John L. Miclot, President and Chief Executive Officer of Tengion. "We believe that the Neo-Kidney Augment product has the potential to provide tremendous advantages for patients suffering from CKD and that there is great need for this important product candidate. The planned enrollment expansion in Sweden and the initiation of U.S. clinical development is very encouraging. We also expect to move forward with the Neo-Urinary Conduit by engaging key opinion leaders and the U.S. Food and Drug Administration (FDA) and for guidance on next phase trials by mid-2014, and we believe the product has the potential to be the new standard of care for bladder cancer patients following bladder removal."
Neo-Kidney Augment Program Update
The Phase 1 trial of the Neo-Kidney Augment being conducted at the Karolinska Institute in Stockholm, Sweden commenced in May 2013 and involves delivery of an active regenerative dose of Neo-Kidney Augment in patients with CKD. The Neo-Kidney Augment is safe and well tolerated in the five patients implanted to date. As noted above, the Company plans to expand enrollment to 15 patients, and all patients in the trial will be followed for up to two years.
The recently initiated U.S. Phase 1 clinical trial will evaluate the safety and delivery of the Company's Neo-Kidney Augment in patients with CKD. It is expected to enroll up to 12 patients and will follow each patient for up to two years. The Company anticipates that it will complete patient enrollment during 2014.
Neo-Urinary Conduit Program Update
Tengion will complete patient enrollment in the ongoing Neo-Urinary Conduit Phase 1 clinical trial and plans to engage key opinion leaders and the FDA for guidance on potential next phase trials by mid-2014. The ongoing Phase 1 trial is designed to translate the surgical procedure successfully used in preclinical animal models into clinical trials with human patients, as well as to assess the safety and preliminary efficacy of the Neo-Urinary Conduit.
About the Neo-Kidney Augment™
The Neo-Kidney Augment is an implant made from a patient's own cells and is intended to catalyze the regeneration of functional kidney tissue in patients with advanced chronic kidney disease (CKD). This increase in functional kidney mass could thereby prevent or delay the need for dialysis and transplant in patients with advanced chronic kidney disease (CKD). According to the United States Renal Data System, there are approximately 26 million adults in the U.S. who have CKD and 100,000 new patients who start on dialysis each year. CKD affects more than 10% of the world's population. Additionally, $39 billion in direct U.S. costs each year are attributable to patients with end-stage renal disease, which is associated with an approximate 20% mortality rate per year and an average life expectancy of a patient initiating dialysis of approximately four years.
About the Neo-Urinary Conduit™
Tengion's Neo-Urinary Conduit is designed to replace the standard of care for bladder cancer patients undergoing cystectomy (removal of bladder). There are over 25,000 cystectomies performed annually in bladder cancer patients in the U.S. and Europe. The Neo-Urinary Conduit is an implant made from a patient's own cells and is intended to catalyze regeneration of native-like urinary tissue, thereby eliminating the need to use bowel tissue in the current standard of care surgery. The Neo-Urinary Conduit is expected to eliminate the short-term and long-term complications associated with use of bowel tissue, such as electrolyte and metabolic disorders, nutritional and therapeutic-agent absorption anomalies, kidney and urinary tract infections, and stone formation. In addition, the Neo-Urinary Conduit is anticipated to improve recovery times, which results in faster hospital discharges compared to the current standard of care.
About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. The Company is currently conducting Phase 1 clinical trials in Sweden and the U.S. for its Neo-Kidney Augment, which is intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease.
A Phase 1 trial for the Company's Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal, is ongoing.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Tengion's plans, potential opportunities, or other expectations, projections, goals, objectives, strategies, timelines, clinical studies, product development and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Tengion's operating performance and financial position, research, development and commercialization of products, the risks and uncertainties associated with meeting the objectives of its clinical studies, including, but not limited to, continued funding, delays or failures in enrollment, and the occurrence of adverse safety events, obtaining regulatory approvals, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
CONTACT: Investor and Media Contact:
Brian Davis
brian.davis@tengion.com
336.201.0155
Source: Tengion, Inc.
in your opinion....., I'm well aware of the many requirements, and also the different exchanges....my comment was meant to indicate that info from Gary has always linked the R/S with an uplist, to say otherwise, IMO, is misleading!
R/S has always been linked with Uplist.....
.49 High..... .058 low
Sure is worth repeating!
PLAINTIFF’s MOTION FOR ACCEPTANCE OF CONSENT
AND ENTRY OF CONSENTED-TO FINAL JUDGMENT AGAINST
ADVANCED CELL TECHNOLOGY, INC.
Plaintiff Securities and Exchange Commission (“SEC”) hereby files the executed Consent of Defendant Advanced Cell Technology, Inc. (“Advanced Cell”) to entry of Permanent Injunction and Other Relief. The Consent and proposed Final Judgment are attached. The SEC respectfully asks the Court to accept the Consent and to enter the proposed Final Judgment, which would resolve all of the SEC’s claims against Advanced Cell.
Dated: December 23, 2013
Respectfully submitted,
/s Drew M. Dorman, Esq., Securities and Exchange Commission
Without admitting or denying the allegations of the complaint (except as to personal and subject matter jurisdiction, which Defendant admits), Defendant hereby consents to the entry of the final Judgment in the form attached hereto (the "Final Judgment") and incorporated by reference herein, which, among other things:
(a) permanently restrains and enjoins Defendant from violations of Sections 5(a) and 5(c) of the Securities Act of 1933 [15 U.S.C. §§ 77e(a) and 77e(c)] and Section 13(a) of the Securities Exchange Act of 1934 [15 U.S.C. § 78m(a)] and Rule 13a-ll thereunder [17 C.F.R. § 240.l3a-ll]; and (b) orders Defendant to pay disgorgement in the amount of $3,500,000, plus prejudgment interest thereon in the amount of $586,619, for a total $4,086,619
IT IS HEREBY FURTHER ORDERED, ADJUDGED, AND DECREED that Defendant is liable for disgorgement of $3,500,000, representing profits gained as a result of the conduct alleged in the Complaint, together with prejudgment interest thereon in the amount of $586,619, for a total of $4,086,619.
Defendant shall satisfy this obligation by paying to the Commission $4,086,619 in six (6) equal installments of $681,104.16, plus post-judgment interest, in accordance with the following schedule:
(1) A payment of $681,104.16 shall be made within fourteen (14) days after the entry of this Final Judgment; and
(2)Subsequently, a total of five installment payments of $681,104.16 each shall be made on the fifteenth (15th) day of each quarter following the entry of this Final Judgment, with the final installment and all remaining balances due on the fifteenth (15th) day of the fifth quarter following entry of this Final Judgment.
PPS on the rise, we've missed you, Gastro...
One of the many remarkable aspects of Advanced Cell Technology it their Pro-life method of harvesting embryonic Stem cells. True Pro-lifers truly support Advanced Cell Technology!
It has more to do with the lack of info when things went ...well...not good in their neobladder trial...which had investors selling...
This is a strange one....traded at over $30-50 per share just a couple of years ago (based on today's share structure)
Thanks for the story. I have "liked" his Facebook page.
.30 pps a new low....tngn....
There is an agreement in principle with the SEC. ACTC is excused from the 12/6/2013 mediation. The process is underway...Like a claim that is submitted to an insurance company...some weeks (some say 8) will go by before the formal approval takes place. When did the clock start on this, I do not know.